FARMINGDALE, N.Y.--(BUSINESS WIRE)--March 1, 2006--Enzo Biochem, Inc. (NYSE:ENZ) announced today that Enzo Therapeutics, its wholly owned subsidiary has received approval from the Committee on Human Research (CHR) at the University of California San Francisco (UCSF) to continue the clinical evaluation of the Company’s Stealth Vector(R) HGTV43(TM) gene construct for HIV-1 infection in a protocol that has been modified to increase the number of stem cells that engraft in the patient’s bone marrow.
